Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

Prevalence of COVID-19 Infection in a Cohort of Patient Infected by the HIV and Patients Taking PrEP Pre-exposure Prophylaxis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04575545

Enrollment

600

Registered

2020-10-05

Start date

2020-10-31

Completion date

2022-04-30

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Virus-HIV

Brief summary

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Interventions

DIAGNOSTIC_TESTSerology test for COVID-19

ELISA test

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged ≥ 18 years * patients infected by the HIV on treatment * patients taking PreP (Pre-exposure prophylaxis (PrEP)) * Being affiliated with or benefiting from a social security scheme

Exclusion criteria

* Subject to a measure for the protection of justice

Design outcomes

Primary

Measure	Time frame
% of patients with positive serological tests for covid-19	3 months

Secondary

Measure	Time frame	Description
Presence and quantification of CD4 / CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19	3 months	% of anti-covid positive cells

Countries

France

Contacts

Primary ContactMyriam BENNANI

m.bennani@hopital-europeen.fr0413428351

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026